Company Overview of Claris Lifesciences Limited
Claris Lifesciences Limited, together with its subsidiaries, manufactures and sells drugs and pharmaceuticals worldwide. The company manufactures and markets products for anesthesia and analgesics, blood products, anti-infectives, plasma volume expanders, critical care, and nephrology areas, as well as for infusion therapy and nutrition applications. It also provides dialysis and transplant range across systems, solutions, medicines, disposables, and equipment. In addition, the company offers injectables for various therapeutic groups, including anti-emetics, CNS, cardiology, anti-malaria, haematinics, etc. It offers its products through various delivery systems, such as glass and plastic bo...
Near Parimal Railway Crossing
Founded in 1994
Key Executives for Claris Lifesciences Limited
Vice Chairman, Managing Director, Member of Share Transfer Committee, Member of Executive Committee, Member of Corporate Social Responsibility Committee and Member of Stakeholders Relationship Committee
Total Annual Compensation: 6.0M
Chief Financial Officer, Whole Time Director, Member of Share Transfer Committee, Member of Executive Committee, Member of Audit Committee, Member of Corporate Social Responsibility Committee and Member of Stakeholders Relationship Committee
Total Annual Compensation: 9.7M
Senior Vice President, Compliance Officer and Company Secretary
Total Annual Compensation: 8.5M
Whole Time Director, Chairman of Executive Committee, Member of Share Transfer Committee and Member of Corporate Social Responsibility Committee
Compensation as of Fiscal Year 2016.
Claris Lifesciences Limited Key Developments
Carlyle Group Reportedly Prepares Bid For Claris Lifesciences's Injectable Drugs Business
Aug 23 16
The Carlyle Group LP (NasdaqGS:CG) to bid for injectable drugs business of Claris Lifesciences Limited (BSE:533288). Carlyle Group to partner with a drug maker to acquire Claris's business that is valued at $400-450 million. Claris has hired Jefferies LLC and Credit Suisse Group AG (SWX:CSGN) to find a buyer for the business.
Claris Lifesciences Limited Reports Un-Audited Standalone and Consolidated Earnings Results for the First Quarter Ended June 30, 2016
Aug 19 16
Claris Lifesciences Limited reported un-audited standalone and consolidated earnings results for the first quarter ended June 30, 2016. For the quarter, on standalone basis, the company reported total income from operations (net) of INR 290.165 million compared to INR 1,407.419 million, loss from operations before other income, finance costs and exceptional items of INR 98.977 million compared to INR 40.647 million, profit from ordinary activities before tax of INR 51.569 million compared to INR 51.622 million and net profit of INR 39.815 million or INR 0.73 per basic and diluted share compared to INR 43.707 million or INR 0.80 per basic and diluted share for the last year.
For the quarter, on consolidated basis, the company reported total income from operations (net) of INR 1,998.322 million compared to INR 1,870.788 million, profit from operations before other income, finance costs and exceptional items of INR 332.644 million compared to INR 357.624 million, profit from ordinary activities before tax of INR 360.925 million compared to INR 339.596 million and net profit of INR 245.123 million or INR 4.03 per basic and diluted share compared to INR 212.814 million or INR 3.53 per basic and diluted share for the last year.
Claris Lifesciences Limited to Report Q1, 2017 Results on Aug 19, 2016
Aug 12 16
Claris Lifesciences Limited announced that they will report Q1, 2017 results on Aug 19, 2016
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|